A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age

NCT05127434 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

36814

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus

Interventions

DRUG: Placebo
DRUG: mRNA-1345

Sponsor

ModernaTX, Inc.